View Item 

Show simple item record

Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis
dc.contributor.authorDomsic, Robyn T.
dc.contributor.authorPokrzywinski, Robin
dc.contributor.authorStassek, Larissa
dc.contributor.authorBenton, Wade W.
dc.contributor.authorVampola, Christa-Lynn
dc.contributor.authorFurst, Daniel E.
dc.contributor.authorChung, Lorinda
dc.contributor.authorSteen, Virginia
dc.contributor.authorMayes, Maureen D.
dc.contributor.authorShah, Ami A.
dc.contributor.authorMolitor, Jerry A.
dc.contributor.authorOliver, Kelly
dc.contributor.authorNagaraja, Vivek
dc.contributor.authorKhanna, Dinesh
dc.date.accessioned2023-04-04T17:38:55Z
dc.date.available2024-04-04 13:38:53en
dc.date.available2023-04-04T17:38:55Z
dc.date.issued2023-03
dc.identifier.citationDomsic, Robyn T.; Pokrzywinski, Robin; Stassek, Larissa; Benton, Wade W.; Vampola, Christa-Lynn ; Furst, Daniel E.; Chung, Lorinda; Steen, Virginia; Mayes, Maureen D.; Shah, Ami A.; Molitor, Jerry A.; Oliver, Kelly; Nagaraja, Vivek; Khanna, Dinesh (2023). "Qualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis." ACR Open Rheumatology 5(3): 132-141.
dc.identifier.issn2578-5745
dc.identifier.issn2578-5745
dc.identifier.urihttps://hdl.handle.net/2027.42/176020
dc.publisherWiley Periodicals, Inc.
dc.titleQualitative Interviews to Assess the Content Validity and Usability of the Electronic Raynaud Diary in Patients with Systemic Sclerosis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelRheumatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176020/1/acr211522_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176020/2/acr211522-sup-0001-Disclosureform.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/176020/3/acr211522.pdf
dc.identifier.doi10.1002/acr2.11522
dc.identifier.sourceACR Open Rheumatology
dc.identifier.citedreferenceBoeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant 2002; 36: 391 – 409.
dc.identifier.citedreferenceMedsger TA, Jr. Epidemiology of systemic sclerosis. Clin Dermatol 1994; 12: 207 – 16.
dc.identifier.citedreferenceWigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994; 120: 199 – 206.
dc.identifier.citedreferenceMayes MD. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 2003; 48: 1190 – 9.
dc.identifier.citedreferenceBarnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012; 24: 165 – 70.
dc.identifier.citedreferenceWigley FM. Clinical practice. Raynaud’s phenomenon. N Engl J Med 2002; 347: 1001 – 8.
dc.identifier.citedreferenceHughes M, Allanore Y, Chung L, et al. Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol 2020; 16: 208 – 21.
dc.identifier.citedreferenceWigley FM. Raynaud’s phenomenon and other features of scleroderma, including pulmonary hypertension. Curr Opin Rheumatol 1996; 8: 561 – 8.
dc.identifier.citedreferenceDenton C, Korn J. Digital ulceration and critical digital ischemia in scleroderma. Scleroderma Care Res 2003; 1: 12 – 6.
dc.identifier.citedreferenceMerkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002; 46: 2410 – 20.
dc.identifier.citedreferenceKhanna PP, Maranian P, Gregory J, et al. The minimally important difference and patient acceptable symptom state for the Raynaud’s Condition Score in patients with Raynaud’s phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis 2010; 69: 588 – 91.
dc.identifier.citedreferencePauling JD, Saketkoo LA, Matucci-Cerinic M, et al. The patient experience of Raynaud’s phenomenon in systemic sclerosis. Rheumatology (Oxford) 2019; 58: 18 – 26.
dc.identifier.citedreferencePauling JD, Domsic RT, Saketkoo LA, et al. Multinational qualitative research study exploring the patient experience of Raynaud’s phenomenon in systemic sclerosis. Arthritis Care Res (Hoboken) 2018; 70: 1373 – 84.
dc.identifier.citedreferenceBlack CM, Halkier-Sorensen L, Belch JJ, et al. Oral iloprost in Raynaud’s phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998; 37: 952 – 60.
dc.identifier.citedreferenceFDA. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. URL: https://www.fda.gov/media/77832/download.
dc.identifier.citedreferenceDziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999; 42: 2646 – 55.
dc.identifier.citedreferenceSteen VD, Medsger TA, Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 1984 – 91.
dc.identifier.citedreferenceMerkel PA, Clements PJ, Reveille JD, et al. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003; 30: 1630 – 47.
dc.identifier.citedreferencePauling JD, Frech TM, Hughes M, et al. Patient-reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis: A SCTC vascular working group report. J Scleroderma Relat Disord 2018; 3: 249 – 52.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr211522_am.pdf
Size:
1.821MB
Format:
PDF
View/Open
Name:
acr211522-sup-0001-Disclosuref ...
Size:
1.240MB
Format:
PDF
View/Open
Name:
acr211522.pdf
Size:
1.021MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.